SecurityGFN / General Finance Corp.
IndustryRetail Stores, Not Elsewhere Classified
Common Shares Outstanding26,757,054 shares (as of 2018-03-31)
Total Insiders21
Total Directors9
Total Officers9

Stock Insider Trading (from SEC Form 4)

GFN / General Finance Corp. Insider Trades

General Finance Corp. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

GFN / General Finance Corp. insiders include Wilson Christopher A, BARRANTES CHARLES E, Baker Gregory B, Marrero Manuel, Harris Susan L, ROSZAK JAMES B, Havner LeeAnn R Miller Jody Edwin, KEENOM BOBBY, GAGNON NEIL, Mourouzis Theodore M., Connell David M, Kluckman Jeffrey A, HAVNER RONALD L JR, Trussler Douglas B, Havner Family Trust, and Littlewood Neil, TASHJIAN LARRY D, WEBER ERIC, Valenta Ronald, BARIBAULT WILLIAM H, .

Insider Roster

Insider Dir Off 10% Shares Owned
HAVNER RONALD L JR 10% Owner
X 3,515,145
Havner Family Trust 10% Owner
X 3,513,145
Havner LeeAnn R 10% Owner
X 3,522,645
Mourouzis Theodore M. President of Pac-Van, Inc.
X 436,542
Valenta Ronald Director, 10% Owner
X X
GAGNON NEIL 10% Owner
X 22,315
Miller Jody Edwin CEO & President, Director
X X 355,156
BARRANTES CHARLES E Chief Financial Officer
X 97,750
Kluckman Jeffrey A Executive Vice President
X 88,788
Wilson Christopher A General Counsel, VP, Secretary
X 103,352
WEBER ERIC CFO of Pac-Van, Inc.
X 29,500
Baker Gregory B CFO of Royal Wolf Holdings
X 61,240
Littlewood Neil CEO of Royal Wolf Holdings
X 103,796
Trussler Douglas B Director
X 2,470,588
TASHJIAN LARRY D Director
X 232,742
ROSZAK JAMES B Director
X 104,463
Marrero Manuel Director
X 136,538
Harris Susan L Director
X 41,913
BARIBAULT WILLIAM H Director
X 29,280
KEENOM BOBBY EVP of Lone Star Tank Rental
X 1,000
Connell David M Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-06-20 4 HAVNER RONALD L JR As trustee of the Havner Family Trust. P I 15,000 3,530,145
2018-06-20 4 Havner LeeAnn R As trustee of the Havner Family Trust. P I 11.95 15,000 3,537,645 42,274,858
2018-06-20 4 Havner Family Trust P D 11.99 15,000 3,528,145 42,302,459
2018-06-19 4 Havner LeeAnn R As trustee of the Havner Family Trust. P I 12.00 5,000 3,522,645 42,271,740
2018-06-19 4 Havner Family Trust P D 12.00 5,000 3,513,145 42,157,740
2018-06-19 4 HAVNER RONALD L JR As trustee of the Havner Family Trust. P I 12.00 5,000 3,515,145 42,181,740
2018-06-19 4 Mourouzis Theodore M. S D 12 -275 436,542 5,238,504
2018-06-19 4 Mourouzis Theodore M. M D 12 978 436,817
2018-06-19 4 Mourouzis Theodore M. S D 11.95 -2,010 435,839 5,208,276
2018-06-19 4 Mourouzis Theodore M. M D 11.95 7,500 437,849
2018-06-18 4 Havner Family Trust P D 11.95 10,000 3,508,145 41,922,333
2018-06-18 4 HAVNER RONALD L JR As trustee of the Havner Family Trust. P I 11.95 10,000 3,510,145 41,946,233
2018-06-18 4 Havner LeeAnn R As trustee of the Havner Family Trust. P I 11.95 10,000 3,517,645 42,035,858
2018-06-13 4 Havner Family Trust P D 11.38 30,000 3,498,145 39,808,890
2018-06-13 4 Havner LeeAnn R As trustee of the Havner Family Trust. P I 11.38 30,000 3,507,645 39,917,000
2018-06-13 4 HAVNER RONALD L JR As trustee of the Havner Family Trust. P I 11.38 30,000 3,500,145 39,831,650
2018-06-12 4 Havner Family Trust P D 11.395 1,219 3,468,145 39,519,512
2018-06-12 4 Havner Family Trust P D 11.4 1,200 3,466,926 39,522,956
2018-06-12 4 Havner LeeAnn R As trustee of the Havner Family Trust P I 11.395 1,219 3,477,645 39,627,765
2018-06-12 4 Havner LeeAnn R As trustee of the Havner Family Trust P I 11.4 1,200 3,476,426 39,631,256
2018-06-12 4 HAVNER RONALD L JR As trustee of the Havner Family Trust P I 11.395 1,219 3,470,145 39,542,302
2018-06-12 4 HAVNER RONALD L JR As trustee of the Havner Family Trust P I 11.4 1,200 3,468,926 39,545,756
2018-06-11 4 HAVNER RONALD L JR As trustee of the Havner Family Trust. P I 11.12 554,641 3,467,726 38,561,113
2018-06-11 4 Havner LeeAnn R As trustee of the Havner Family Trust. P I 11.12 554,641 3,475,226 38,644,513
2018-06-11 4 Havner Family Trust P D 11.12 554,641 3,465,726 38,538,873
2018-06-12 4 WEBER ERIC A D 10,000 29,500
2018-06-12 4 Wilson Christopher A A D 5,000 103,352
2018-06-12 4 Kluckman Jeffrey A A D 10,000 88,788
2018-06-12 4 BARRANTES CHARLES E A D 5,000 97,750
2018-06-12 4 Miller Jody Edwin A D 30,455 355,156
2018-06-11 4 GAGNON NEIL By self as Trustee of Gagnon Securities LLC Profit Sharing Plan S I 11.1201 -1,359 22,315 248,145
2018-06-11 4 GAGNON NEIL By Limited Partner of the Family Partnership S I 11.1201 -37,833 193,542 2,152,206
2018-06-11 4 GAGNON NEIL S D 11.1201 -106,493 696,906 7,749,664
2018-06-11 4 GAGNON NEIL By Managing Member as General Partner of Darwin Partnership S I 11.1006 -5,453 133,490 1,481,819
2018-06-11 4 GAGNON NEIL By Managing Member as General Partner of Gagnon Investment Associates S I 11.1006 -45,206 1,187,665 13,183,794
2018-06-07 4 GAGNON NEIL By Managing Member as General Partner of Darwin Partnership S I 11.0893 -1,184 1,197,391 13,278,228
2018-06-07 4 GAGNON NEIL By Managing Member as General Partner of Gagnon Investment Associates S I 11.0893 -9,823 2,291,319 25,409,124
2018-06-07 4 Havner LeeAnn R As trustee of the Havner Family Trust. P I 11.04 7,778 2,920,585 32,243,258
2018-06-07 4 HAVNER RONALD L JR As trustee of the Havner Family Trust. P I 11.04 7,778 2,913,085 32,160,458
2018-06-07 4 Havner Family Trust P D 11.04 7,778 2,911,085 32,138,378
2018-06-07 4 Havner LeeAnn R As trustee of the Havner Family Trust. P I 11.04 7,778 2,920,585 32,243,258
2018-06-06 4 Havner LeeAnn R As trustee of the Havner Family Trust. P I 11.00 5,162 2,912,807 32,040,877
2018-06-06 4 Havner Family Trust P D 11.00 5,162 2,903,307 31,936,377
2018-06-06 4 HAVNER RONALD L JR As trustee of the Havner Family Trust. P I 11.00 5,162 2,905,307 31,958,377
2018-06-06 4 GAGNON NEIL By Managing Member as General Partner of Darwin Partnership S I 11.10 -583 1,198,575 13,304,182
2018-06-06 4 GAGNON NEIL By Managing Member as General Partner of Gagnon Investment Associates S I 11.10 -4,839 2,301,142 25,542,676
2018-06-05 4 GAGNON NEIL By Managing Member as General Partner of Darwin Partnership S I 11.1006 -947 1,199,158 13,311,373
2018-06-05 4 GAGNON NEIL By Managing Member as General Partner of Gagnon Investment Associates S I 11.1006 -7,854 2,305,981 25,597,773
2018-06-04 4 Havner Family Trust P D 11.10 14,000 2,898,145 32,169,410
2018-06-04 4 Havner LeeAnn R As trustee of the Havner Family Trust P I 11.10 14,000 2,907,645 32,274,860
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

9h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

9h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Trinity Industries Inc.: Spin-Off Entity Does Not Look Overly Promising

2018-06-11 seekingalpha
In December 2017 Trinity Industries Inc.’s (NYSE:TRN) announced that they would spin-off their infrastructure related businesses into its own separate entity called Arcosa Inc. (Arcosa). Arcosa is expected to have approximate revenue of $1.5 billion post spin, leaving TRN with the rail-related businesses (Rail and Railcar Leasing) and approximate forecasted revenue of $2.4 billion (May 2018 Investor Presentation). (13-0)

General Finance Corp.: Cyclical Upside Has Been Realized

2018-06-01 seekingalpha
I believe that General Finance Corporation (NASDAQ:GFN) is now trading beyond its full intrinsic and an investor may want to reevaluate their position at these levels in order to lock in some gains at a price that may be a bit irrational in relation to the future economics of the business. (3-0)

General Finance's (GFN) CEO Jody Miller on Q3 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Welcome to the General Finance Corporation's Earnings Conference Call for the Third Quarter ended March 31, 2018. Hosting the call today from the company's corporate office in Pasadena, California are Mr. Jody Miller, President and Chief Executive Officer and Mr. Charles Barrantes, Executive Vice President and Chief Financial Officer. (3-0)

Robust Private Sector Hiring in March: 5 Top-Ranked Picks

2018-04-05 zacks
U.S. private sector employers made robust job additions in March, per a Automatic Data Processing Inc. ("ADP") and Moody’s Analytics report dated Apr 4. In fact, data from the same proved that the negative market sentiment about U.S. tariffs imposed on steel and aluminum by President Trump was overblown. Also, the U.S. Labor Department’s report released on Mar 9 showed that the economy added 313,000 jobs in February 2018, exceeding the consensus estimate of 208,000. (67-0)

Avis' (CAR) Budget Car Rental Starts Operations in Taiwan

2018-03-15 zacks
Avis Budget Group, Inc. (CAR - Free Report) , through its Budget Car Rental, has launched vehicle rental services in Taiwan. Budget Taiwan is an independently-owned and operated licensee of Budget Car Rental. It is operated by Anweisi Car Rental Company Ltd, which has years of experience in offering variety of mobility services on the island. Avis Budget’s new facilities are presently located in Taoyuan international airport, Taichung international airport, Kaohsiung international airport and Taipei’s main station. (26-0)